Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib in NSCLC With EGFR Exon 20 Insertion Mutations
NCT05466149Phase 2Active, not recruiting
- Sponsor
- Allist Pharmaceuticals
- Start
- Sep 2022
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by Allist Pharmaceuticals. Started Sep 2022; status: active, not recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05466149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05466149.